HUE059644T2 - Módosított IgG ellenanyagok, amelyek magas affinitással, aviditással és specificitással megkötik a -béta1 transzformáló növekedési faktort - Google Patents
Módosított IgG ellenanyagok, amelyek magas affinitással, aviditással és specificitással megkötik a -béta1 transzformáló növekedési faktortInfo
- Publication number
- HUE059644T2 HUE059644T2 HUE16709666A HUE16709666A HUE059644T2 HU E059644 T2 HUE059644 T2 HU E059644T2 HU E16709666 A HUE16709666 A HU E16709666A HU E16709666 A HUE16709666 A HU E16709666A HU E059644 T2 HUE059644 T2 HU E059644T2
- Authority
- HU
- Hungary
- Prior art keywords
- beta1
- avidity
- specificity
- growth factor
- high affinity
- Prior art date
Links
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE059644T2 true HUE059644T2 (hu) | 2022-12-28 |
Family
ID=55524479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16709666A HUE059644T2 (hu) | 2015-03-04 | 2016-03-03 | Módosított IgG ellenanyagok, amelyek magas affinitással, aviditással és specificitással megkötik a -béta1 transzformáló növekedési faktort |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11325970B2 (OSRAM) |
| EP (3) | EP4495137A3 (OSRAM) |
| JP (1) | JP6745275B2 (OSRAM) |
| KR (3) | KR20240076851A (OSRAM) |
| CN (1) | CN107787329B (OSRAM) |
| AR (1) | AR103840A1 (OSRAM) |
| AU (1) | AU2016226098B2 (OSRAM) |
| DK (1) | DK3265487T3 (OSRAM) |
| ES (2) | ES2927297T3 (OSRAM) |
| HR (1) | HRP20221142T1 (OSRAM) |
| HU (1) | HUE059644T2 (OSRAM) |
| IL (1) | IL254239B2 (OSRAM) |
| LT (1) | LT3265487T (OSRAM) |
| MX (1) | MX382703B (OSRAM) |
| PL (1) | PL3265487T3 (OSRAM) |
| PT (1) | PT3265487T (OSRAM) |
| RS (1) | RS63589B1 (OSRAM) |
| RU (1) | RU2728858C2 (OSRAM) |
| SG (2) | SG11201707109XA (OSRAM) |
| SI (1) | SI3265487T1 (OSRAM) |
| TW (1) | TWI733661B (OSRAM) |
| WO (1) | WO2016141245A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| JP2019509737A (ja) * | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| TW202421659A (zh) | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| TWI856437B (zh) * | 2017-01-20 | 2024-09-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| CA3104274A1 (en) * | 2018-05-10 | 2019-11-14 | Mirabiologics Inc. | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
| US12252531B2 (en) | 2018-07-11 | 2025-03-18 | Scholar Rock, Inc. | Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| MXPA06011199A (es) * | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| JP2008513542A (ja) | 2004-09-22 | 2008-05-01 | ジェンザイム・コーポレイション | 免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PL1874818T3 (pl) | 2005-04-22 | 2011-09-30 | Lilly Co Eli | Przeciwciała swoiste wobec TGF-beta 1 |
| JP2009521496A (ja) | 2005-12-23 | 2009-06-04 | イーライ リリー アンド カンパニー | ＴＧＦ−β結合組成物 |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| US8048421B2 (en) | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
| MX2009003518A (es) * | 2006-10-03 | 2009-08-25 | Genzyme Corp | Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. |
| EP2313109A2 (en) | 2008-07-02 | 2011-04-27 | Emergent Product Development Seattle, LLC | Il6 immunotherapeutics |
| ES2702049T3 (es) * | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MY171135A (en) | 2011-06-03 | 2019-09-27 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| WO2014018572A2 (en) | 2012-07-23 | 2014-01-30 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| BR112015021595A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
| US9598486B2 (en) * | 2013-03-20 | 2017-03-21 | Genzyme Corporation | Methods for treating osteogenesis imperfecta |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 MX MX2017011252A patent/MX382703B/es unknown
- 2016-03-03 KR KR1020247016764A patent/KR20240076851A/ko active Pending
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en not_active Ceased
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 KR KR1020237024971A patent/KR102668864B1/ko active Active
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 ES ES22180865T patent/ES2994790T3/es active Active
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 EP EP24203381.9A patent/EP4495137A3/en active Pending
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 EP EP22180865.2A patent/EP4163299B1/en active Active
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active Active
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US12162933B2/en active Active
-
2024
- 2024-11-06 US US18/939,307 patent/US20250179163A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290412A (en) | New monoclonal antibodies to cd47 and their uses | |
| HUE059644T2 (hu) | Módosított IgG ellenanyagok, amelyek magas affinitással, aviditással és specificitással megkötik a -béta1 transzformáló növekedési faktort | |
| IL272183A (en) | Anti-cd8 antibodies and uses thereof | |
| IL271901A (en) | Anti-CD8 antibodies and their uses | |
| HUE054384T2 (hu) | EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók | |
| HUE055112T2 (hu) | Bispecifikus antitest konstrukciói, amelyek DLL3-hoz és CD3-hoz kötõdnek | |
| HUE057837T2 (hu) | PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik | |
| LT3347379T (lt) | Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos | |
| ZA201704117B (en) | Cd47 antibodies, methods, and uses | |
| HUE046412T2 (hu) | CDH19 és CD3 elleni ellenanyag -konstrukciók | |
| LT3328891T (lt) | Antikūno konstruktai, skirti flt3 ir cd3 | |
| HUE071182T2 (hu) | EGFR és CMET kötõ antitestek | |
| HUE045216T2 (hu) | Anti-CD79B antitestek és alkalmazási eljárások | |
| HUE059338T2 (hu) | Ellenanyagok, alkalmazások és eljárások | |
| WO2014150877A3 (en) | Anti-tau antibodies and methods of use | |
| HUE059655T2 (hu) | Új anti-humán GPVI antitestek és felhasználásuk | |
| IL262404A (en) | Antibodies, antibody fragments, and their immunosuppressants against ror2 and their uses | |
| EP3149046A4 (en) | Humanized anti-cd19 antibody and use thereof | |
| IL254238B (en) | Scfv-fc dimers that bind transforming growth factor-ß1 with high affinity, avidity and specificity | |
| EP3253789A4 (en) | Anti-salmonella antibodies and uses thereof | |
| EP3209686A4 (en) | Monoclonal anti-gpc-1 antibodies and uses thereof | |
| WO2015069718A3 (en) | Pre-haptoglobin-2 monoclonal antibodies and uses thereof | |
| HK40097434A (zh) | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 | |
| HK1262556A1 (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| HK40017842A (en) | Anti-c5 antibodies and uses thereof |